Here’s what the clinical evidence actually shows.
If you’ve been researching myopia control options for your child, you’ve probably come across Stellest lenses and the bold claim that they slow myopia progression by 67%. As a parent, it’s natural to ask: Is that real, or is it marketing?
It’s a fair question. The eyecare industry has no shortage of products that promise more than they deliver. So before recommending Stellest lenses to families at Urban Optique & Eyecare in Chandler, Arizona, I want to walk you through exactly what the clinical evidence shows, what the FDA authorization actually means, and, critically, what conditions have to be met for Stellest lenses to deliver those results.
The short answer is yes, Stellest lenses work. But there are important nuances every parent should understand before starting treatment.
What “Working” Actually Means for a Myopia Control Lens
First, let’s set the right expectations. No myopia control treatment (not Stellest lenses, not orthokeratology, not contact lens-based options) stops myopia entirely. The goal is to slow the rate of progression, which means your child’s prescription still changes, but more slowly than it would with regular single-vision glasses.
This matters enormously for long-term eye health. Research published in Optometry and Vision Science by Bullimore and Brennan established that every diopter of myopia your child avoids accumulating carries a 40% reduction in their lifetime risk of myopic maculopathy, one of the leading causes of irreversible vision loss in adults who were myopic as children. Slowing progression by even half a diopter per year compounds into significant protection over a childhood. If you’d like a deeper understanding of how myopia develops and why early intervention matters, our post on Understanding Myopia in Children is a good place to start.
So when we ask “do Stellest lenses work,” the real question is: do they meaningfully slow how fast myopia worsens? And do they do it better than doing nothing, or better than standard glasses?
The answer to both is yes, and there’s now a substantial body of evidence to back that up.
Why Myopia Management Has Become Urgent: Not Optional
Before diving into what Stellest does, it’s worth stepping back and understanding why myopia management matters at all, because the scale of what’s happening to children’s eyes globally changes how we should think about treatment decisions.
A landmark study published in Ophthalmology by Holden and colleagues projects that by 2050, nearly half the world’s population will be myopic, up from about 23% in 2000. In East Asian countries, rates among school-age children already exceed 80%. The United States is following a similar trajectory, driven by increased near-work demands, reduced outdoor time, and earlier exposure to screens during the years when eyes are most developmentally active.
For families in the East Valley, the picture has its own nuances. Despite Arizona’s abundant sunlight, which research consistently links to a protective effect against myopia onset, indoor learning environments, extended screen time, and the shift toward year-round air-conditioned living have eroded that natural advantage for many children. We see this reflected in our patient population: kids who spend plenty of time outside but still progress rapidly because of how they spend their indoor hours.
Myopia is not just a vision inconvenience. It is a pediatric eye health issue with serious adult consequences. Every diopter of myopia your child accumulates during childhood increases their lifetime risk of retinal detachment, glaucoma, myopic maculopathy, and cataracts in a dose-dependent way. The children who end up with high myopia (-6.00 diopters or worse) carry a dramatically elevated risk of vision-threatening complications as adults.
This is why myopia management is not a luxury add-on to glasses. It is, for many children, the most important eye health decision their parents will make on their behalf. And it is most effective when it starts early, which brings us to a question most competing articles never address.
The Clinical Evidence: What the Studies Actually Show
The Original Two-Year Randomized Controlled Trial
The foundation of Stellest’s efficacy claims comes from a rigorous randomized controlled trial (the gold standard of clinical research) conducted in partnership with Wenzhou Medical University in China and published in JAMA Ophthalmology by Bao and colleagues in 2022. In this study, myopic children aged 8 to 13 were randomly assigned to wear either Stellest lenses or standard single-vision lenses for two years.
The results among children who wore Stellest lenses for at least 12 hours per day:
- 67% less myopia progression compared to single-vision lens wearers
- 60% less axial elongation, the physical lengthening of the eyeball that drives myopia
- Nearly 1.00 diopter less final myopia over two years
- Only 0.28mm of total axial growth over the full two-year period
These are not trivial numbers. One diopter less myopia over two years translates to a meaningfully lower prescription, and based on the Bullimore & Brennan research in Optometry and Vision Science, a 40% reduction in lifelong risk of myopic maculopathy for every diopter avoided.
The Five-Year and Six-Year Follow-Up Data
What separates Stellest from every competing myopia control product in eyeglass form is the depth of its long-term evidence base. Essilor has continued following the original trial participants well beyond the initial two-year study period, and the results have only strengthened with time.
The peer-reviewed five-year results, published in Eye and Vision by Li, Huang, and colleagues in March 2025, showed:
- Significantly slowed myopia progression and axial elongation sustained across the full five-year period
- An average saving of three years of myopia development compared to single-vision lens wearers
- A meaningful reduction in the risk of progressing to high myopia
Then in April 2025, EssilorLuxottica presented six-year data at the China Optometry & Ophthalmology Conference (COOC), the most comprehensive long-term dataset available for any spectacle-based myopia control lens, with findings from Prof. Jinhua Bao’s team at Wenzhou Medical University showing:
- 1.95 diopters less myopia progression (57%) compared to an extrapolated single-vision control group
- 0.81mm less axial elongation (52%) over six years
- Efficacy sustained up to age 19, meaning the lenses continued working through the teenage years, not just in early childhood
High myopia (typically defined as -6.00 diopters or worse) is the threshold where the most serious long-term complications become significantly more likely. Nearly two diopters of protection over six years represents a clinically meaningful reduction in a child’s lifetime risk of reaching that threshold. The study is currently entering its seventh year, with participants now aged 15 to 20. No other spectacle lens for myopia control has this level of longitudinal evidence behind it.
FDA Authorization: What It Means and Why It Matters
In September 2025, Stellest lenses became the first FDA-authorized eyeglass lenses specifically designed to slow myopia progression in children, a landmark development that most competing blogs haven’t yet addressed. You can read the FDA’s official press announcement directly on the FDA website.
It’s worth understanding what FDA authorization actually means, because the terminology matters. FDA authorization is not the same as FDA approval. Approval is reserved for drugs and certain high-risk medical devices. But authorization is far from a rubber stamp. It requires manufacturers to submit clinical evidence demonstrating both safety and efficacy to a rigorous, independently reviewed standard. The FDA evaluated Stellest’s clinical trial data and concluded the evidence supports the claim that the lenses slow myopia progression in children.
For parents who are understandably skeptical of health product marketing, this independent regulatory review is the most objective external validation currently available. The 67% figure is not just an Essilor press release. It has been reviewed by the same federal body that regulates medical devices for patient safety.
The Compliance Factor: Where the 67% Comes From (and Why It Matters)
Here’s where I want to be completely transparent with you, because this detail doesn’t always get the attention it deserves.
The 67% reduction in myopia progression documented in the Bao et al. JAMA Ophthalmology trial was measured specifically in children who wore Stellest lenses for at least 12 hours every day, not most days but every day. The full-time wearers in the study averaged around 13.5 hours of daily wear.
Children who wore the lenses for fewer hours showed meaningfully less benefit. The study data shows a clear dose-response relationship: more wearing time correlates directly with better outcomes. Compliance is not a footnote. It is a core variable in whether the treatment works.
This is not a flaw in the technology. It is how myopia control works biologically. The optical signal that Stellest’s H.A.L.T. technology sends to slow eye elongation needs consistent, daily exposure to be effective. Think of it like sunscreen: it only protects the skin that’s covered, and only on the days you apply it. Wearing the glasses six days a week instead of seven does not give you 85% of the benefit, because the biology doesn’t work that way.
What This Means Practically
Twelve hours of daily wear is achievable for most school-age children. It roughly means putting glasses on when they wake up and taking them off at bedtime. But it does require building a consistent habit, and it’s worth having an honest conversation with your child about why wearing time matters before you invest in treatment.
Practical strategies that help families hit the wearing time target include: keeping a backup pair at school, making glasses part of the morning routine before any screens or devices, and framing compliance in terms your child understands: protecting their eyes now so they do not end up with a much stronger prescription as a teenager. Children who understand why they’re wearing the lenses tend to be significantly more compliant than those who are simply told to keep their glasses on.
At Urban Optique & Eyecare, we discuss compliance in detail with every family before prescribing Stellest lenses. We also schedule follow-up appointments every six months to monitor prescription changes and overall visual health, so we can assess whether the lenses are working as expected and adjust the plan if needed. We see families from across the East Valley for myopia management, including Chandler, Gilbert, Queen Creek, San Tan Valley, Mesa, Tempe, Ahwatukee, and Phoenix, and Stellest lenses are available to any child who visits our Chandler office.
The Age Window: When Should You Start?
This is a question most competing articles skip entirely, and it is one of the most important questions a parent can ask, because the timing of when you start myopia management significantly affects how much total protection you’re able to provide.
The earlier you start, the more total protection you can accumulate. Myopia progresses most rapidly between the ages of 8 and 14, with progression rates typically slowing significantly after age 16 as the eye approaches adult stability. A child who starts Stellest treatment at age 7 and wears them consistently through age 14 accumulates seven years of treatment effect during the highest-risk window. A child who starts at age 11 gets three years in that same window.
The math is straightforward: if Stellest slows progression by 67%, then starting earlier means 67% of a larger total progression is being protected. The absolute diopters avoided is greater when treatment starts young. This is consistent with the International Myopia Institute’s Clinical Management Guidelines, which recommend initiating myopia control as soon as progression is confirmed, regardless of how mild the initial prescription is.
What Happens If Treatment Starts Late
Starting myopia management at age 12 or 13 is still worthwhile. It is never “too late” to slow progression. But the returns are more modest than they would have been if treatment began at 7 or 8. This is partly because the eye is already closer to its adult size, and the most aggressive period of axial elongation is nearly complete.
If your child is in their mid-teens and already significantly myopic, the conversation shifts somewhat. We focus on maintaining stability and monitoring for complications rather than the dramatic progression-slowing achievable in younger children. This is one reason why we recommend a myopia management consultation as soon as a child is first diagnosed with myopia, regardless of how mild the prescription appears at diagnosis. Mild myopia today is not a guarantee of mild myopia at age 18.
Is Stellest Appropriate for Teenagers?
Yes, and the six-year data now answers this definitively. The COOC 2025 findings confirmed that Stellest’s efficacy is sustained up to age 19, with participants aged between 14 and 19 at the time of the sixth-year follow-up still showing meaningful slowing of both myopia progression and axial elongation. This is no longer a theoretical assumption. It is documented in the clinical data. We prescribe Stellest for teenagers at Urban Optique & Eyecare, and for adolescents who are still actively progressing, it remains one of the strongest evidence-based options available. For teenagers who have plateaued and are approaching adult prescription stability, the clinical calculus changes, and we may recommend monitoring rather than active treatment. This is an individualized decision made based on each patient’s progression rate, prescription history, and age.
How We Monitor Whether Stellest Is Actually Working
This is another area where most competing practices and most competing blog articles are silent, and it matters enormously.
Here’s the critical point: consistent follow-up is what separates effective myopia management from simply wearing a different pair of glasses. Myopia management requires monitoring over time to assess whether a treatment is producing the expected slowdown in progression for that individual child.
The International Myopia Institute’s 2019 Clinical Management Guidelines identify structured, regular monitoring as a core requirement of evidence-based myopia management practice.
How We Monitor Progress at Urban Optique & Eyecare
At Urban Optique & Eyecare, we schedule follow-up appointments every six months for every child on a myopia management plan. At each visit, we review prescription changes, assess visual comfort with the lenses, and discuss wearing habits and compliance honestly. If prescription progression appears faster than expected, we reassess the treatment approach rather than simply renewing the prescription and sending the family home.
This structured follow-up is what allows us to catch problems early and adjust the plan before a child accumulates more myopia than necessary.
What Happens If Stellest Is Not Producing the Expected Response
If a child is wearing their Stellest lenses consistently and prescription progression is still faster than expected, we reassess. This may mean transitioning to a contact lens-based modality such as orthokeratology or MiSight, or combining Stellest glasses with a contact lens option for greater coverage across the waking day. The right next step depends on the child’s age, lifestyle, and how their eyes are responding.
How Stellest Compares to Other Myopia Control Options
Parents often want to understand how Stellest stacks up against other treatments before deciding. Here’s an honest comparison, including how these treatments can be combined, which most competing articles never discuss.
Stellest lenses vs. standard single-vision glasses: Stellest is significantly more effective at slowing progression. Standard glasses correct blurry vision but do nothing to slow eye elongation. If myopia control is the goal, standard glasses alone are not a sufficient management strategy.
Stellest lenses vs. orthokeratology (ortho-k): Both treatments show comparable efficacy in the clinical literature. Ortho-k involves rigid contact lenses worn overnight that temporarily reshape the cornea, eliminating the need for daytime glasses or contacts. It’s a strong option but requires children to be mature enough for overnight contact lens wear. Stellest is often the better starting point for younger children or those not yet ready for contacts.
Stellest lenses vs. MiSight daily contact lenses: MiSight is an FDA-approved soft contact lens for myopia control with strong multi-year trial data. Like ortho-k, it requires contact lens wear. Some families use both Stellest glasses and MiSight contacts, wearing the contacts during sports or active days and the Stellest glasses during school hours and at home, combining the benefits of both modalities across the waking day.
Combination therapy (when Dr. Simms uses more than one approach): For children progressing faster than expected on Stellest alone, we may recommend transitioning to orthokeratology or layering Stellest glasses with MiSight daily contact lenses for greater coverage across the waking day. Myopia management is not a set-and-forget prescription. It is an active, responsive treatment plan that we adjust as your child’s eyes and circumstances evolve.
The right starting point depends on your child’s age, prescription, progression rate, lifestyle, and comfort with different treatment modalities. We assess all of these factors during a myopia management consultation at Urban Optique & Eyecare.
What Makes Stellest Different: A Quick Look at the Science
Without getting too technical, it’s worth understanding why Stellest lenses work, because it explains why they outperform standard glasses so dramatically.
Your child’s myopia worsens when the eyeball grows too long, a process called axial elongation. This growth is partly driven by the optical signals the eye receives. When light focuses behind the retina, the eye interprets this as a biological signal to keep growing.
Stellest lenses use H.A.L.T. technology (Highly Aspherical Lenslet Targets) consisting of 1,021 tiny lenslets arranged in 11 concentric rings across the lens surface. These lenslets create a volume of myopic defocus, a zone where light converges in front of the retina rather than behind it, sending the eye a signal to slow its elongation.
Critically, the central zone of the lens provides normal, clear single-vision correction. Your child sees sharply through the center of the lens. The myopia-control signal works simultaneously in the peripheral visual field without compromising clarity for reading, screens, sports, or any other daily activity.
In the Bao et al. JAMA Ophthalmology trial, 90% of children fully adapted within three days and 100% within one week. Comfort ratings were excellent across the board, which matters practically, because a lens a child won’t wear consistently won’t produce results.
Cost, Insurance, and FSA/HSA: What Parents Actually Want to Know
No other myopia control blog in this space addresses this directly, so let’s be straightforward about it.
What Stellest lenses cost: Stellest lenses carry a premium over standard single-vision lenses because of the specialized manufacturing technology involved. The exact cost varies depending on the frame, lens index, and any additional coatings. We provide a full cost breakdown at Urban Optique & Eyecare before any treatment begins. There are no surprises at pickup.
What vision insurance typically covers: Based on our experience at Urban Optique & Eyecare, VSP can be applied toward the frame portion of your child’s Stellest lenses. The Stellest lens itself is not currently covered by VSP as a myopia management benefit, but we offer an in-house discount of 20% off the lens cost for VSP members. If you carry a different vision plan, we recommend contacting your provider directly to ask about myopia management lens coverage, as benefits vary and the landscape is evolving as awareness of myopia management grows.
FSA and HSA eligibility: Prescription eyeglasses, including Stellest lenses, are generally FSA and HSA eligible expenses. This means you can use pre-tax dollars to offset the cost of your child’s lenses, which meaningfully reduces the net out-of-pocket impact. If you have an FSA with a use-it-or-lose-it deadline at the end of the calendar year, myopia management is an excellent use of remaining funds.
The long-term cost perspective: It’s worth weighing the cost of Stellest lenses against the cost of doing nothing. Children whose myopia progresses to high myopia levels face not only a lifetime of stronger prescriptions and more expensive lenses, but also a significantly elevated risk of conditions like retinal detachment and myopic maculopathy that carry their own treatment costs and quality-of-life consequences. Framed this way, myopia management is not an optional premium. It is an investment in preventing a more expensive and serious problem later.
Are There Any Other Downsides?
In the interest of full transparency, here are the remaining considerations worth stating plainly:
Compliance dependency: As discussed above, reduced wearing time means reduced benefit. This isn’t unique to Stellest. All myopia control treatments require consistency, and this is the single most important variable within your family’s control.
Not a cure: Myopia control slows progression; it doesn’t reverse existing myopia or stop it completely. Your child will still need glasses, and their prescription may still change, just more slowly than it would without treatment.
Frame fitting precision is essential: Because the lenslets need to align correctly with your child’s visual axis, the quality of the dispensing process matters significantly. At Urban Optique & Eyecare, we carefully assess pantoscopic angle, vertex distance, and frame stability during dispensing to ensure the child consistently looks through the correct optical zone of the lens. This is an area where getting fitted at a practice experienced with Stellest makes a measurable difference in real-world outcomes.
The Bottom Line: Do Stellest Lenses Work?
Yes. With the right expectations, consistent wear, proper clinical monitoring, and timely intervention, Stellest lenses are one of the most effective and well-evidenced myopia control options currently available in eyeglass form.
The two-year randomized controlled trial data published in JAMA Ophthalmology is strong. The peer-reviewed five-year results in Eye and Vision are compelling. The six-year COOC 2025 data showing nearly 2 diopters of protection and efficacy confirmed through age 19, makes Stellest the most longitudinally evidenced spectacle lens for myopia control available today. The FDA De Novo authorization provides independent regulatory validation that no competing spectacle product holds. The compliance requirements are real but achievable. The age window matters, and starting early produces materially better lifetime protection. And consistent, structured follow-up matters: reviewing progression at regular intervals, as recommended by the International Myopia Institute, is the difference between managing your child’s myopia proactively and simply renewing the prescription year after year.
What most competing articles won’t tell you is that Stellest lenses work best as part of a comprehensive myopia management program, not as a lens you pick up and wear without structured follow-up. At Urban Optique & Eyecare, that’s exactly how we approach them. The lens is one tool. The clinical relationship, the monitoring, and the willingness to adjust the plan when needed are what make the difference between good outcomes and great ones.
Ready to Find Out if Stellest Lenses Are Right for Your Child?
Every child’s eyes are different, and myopia control is not one-size-fits-all. The first step is a comprehensive children’s eye exam that evaluates your child’s myopia in full, not just a routine prescription check.
At Urban Optique & Eyecare in Chandler, AZ, Dr. Simms evaluates each child’s myopia individually and builds a customized treatment plan based on their progression rate, age, and lifestyle. Families travel from across the East Valley, including Chandler, Gilbert, Queen Creek, San Tan Valley, Mesa, Tempe, Ahwatukee, and Phoenix, to receive myopia management care at our practice.
Book a Myopia Management Consultation or call us at 480-802-7170 to get started.
Related Reading
